The future of monitoring drug activity markers during therapy

YORK, U.K. - Sept. 9, 2019 - PRLog -- Pharmaceutical Industry's drive to use precision medicine is definitely a move that patients and clinicians welcome in delivering the best outcomes. However, there is also a need for the Industry to focus on patient-experience and clinician-needs when monitoring drug activity markers during therapy. For example, addressing patient anxiety, the speed of results and clinician workloads.

This of course requires a flexible testing method.

So, are there drug therapy monitoring methods that can address patient anxiety and help reduce hospital or medical centre visits while also offering a more appealing solution to tight healthcare budgets and reduce front-line staff workload?

The answer

Companion and complementary lateral flow near-patient tests are being utilised extensively across regulated industries for the rapid production of qualitative, semi- and fully-quantitative results.

The technology is favoured for its ease of use, cost-effectiveness and the ability to be configured to detect a multitude of markers in various samples, and in a variety of near-patient, home, over the counter and clinical testing scenarios.

Also, utilising lateral flow with a smartphone or desktop reader data solution is revolutionising how healthcare providers assess, diagnose and monitor disease status: these data solutions are creating value for all stakeholders via the production of real-time data.

The future

Lean more about the future of monitoring drug activity markers during therapy at https://www.abingdonhealth.com/articles/future-monitoring-drug-therapy/.